Ramalingam, S., Siamakpour-Reihani, S., Bohannon, L., Ren, Y., Sibley, A., Nixon, A., … Sung, A. D. (2020). Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT. In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (Vol. 26, pp. S48–S49). Orlando, FL: ELSEVIER SCIENCE INC.

Ramalingam, Sendhilnathan, Sharareh Siamakpour-Reihani, Lauren Bohannon, Yi Ren, Alexander Sibley, Andrew Nixon, Jing Lyu, et al. “Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT.” In BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 26:S48–49. ELSEVIER SCIENCE INC, 2020.

Ramalingam S, Siamakpour-Reihani S, Bohannon L, Ren Y, Sibley A, Nixon A, et al. Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT. In: BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC; 2020. p. S48–9.

Ramalingam, Sendhilnathan, et al. “Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT.” BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, vol. 26, no. 3, ELSEVIER SCIENCE INC, 2020, pp. S48–49.

Ramalingam S, Siamakpour-Reihani S, Bohannon L, Ren Y, Sibley A, Nixon A, Lyu J, Xie J, Choi T, Gasparetto C, Horwitz ME, Long GD, Lopez R, Rizzieri DA, Sarantopoulos S, Chao NJ, Sung AD. Phase II Trial of Pasireotide to Prevent GI Toxicity and Acute Gvhd in Allogeneic HSCT. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. ELSEVIER SCIENCE INC; 2020. p. S48–S49.